LifeSci Venture Partners

Team

  Paul Yook   Paul has over 20 years of healthcare investment and finance experience and in 2017 founded LifeSci Venture Partners. He led LifeSci's investments in Rocket Pharma, Engage Therapeutics, Biolinq and Allakos. In 2014, Paul launched the BioShares biotechnology ETFs (NYSE: BBC & BBP) which utilize innovative and sector-specific passive index strategies and have delivered the strongest performance metrics (Sharpe ratio and total return) in their class. He previously worked at Galleon Management, as a research analyst and healthcare hedge fund portfolio manager, and in the healthcare investment banking groups of Goldman Sachs and UBS.  Paul is a passionate surfer, having lived for 3 years in Hawaii, is a mediocre but improving chess player in an effort to keep up with his two young kids, and makes an outstanding açaí bowl. He earned a B.S.E in Economics from the Wharton School and a B.A. in Biochemistry from the College of Arts and Sciences at the University of Pennsylvania.

Paul Yook

Paul has over 20 years of healthcare investment and finance experience and in 2017 founded LifeSci Venture Partners. He led LifeSci's investments in Rocket Pharma, Engage Therapeutics, Biolinq and Allakos. In 2014, Paul launched the BioShares biotechnology ETFs (NYSE: BBC & BBP) which utilize innovative and sector-specific passive index strategies and have delivered the strongest performance metrics (Sharpe ratio and total return) in their class. He previously worked at Galleon Management, as a research analyst and healthcare hedge fund portfolio manager, and in the healthcare investment banking groups of Goldman Sachs and UBS.

Paul is a passionate surfer, having lived for 3 years in Hawaii, is a mediocre but improving chess player in an effort to keep up with his two young kids, and makes an outstanding açaí bowl. He earned a B.S.E in Economics from the Wharton School and a B.A. in Biochemistry from the College of Arts and Sciences at the University of Pennsylvania.

  Andrew McDonald, PhD   Andrew co-founded LifeSci Partners in 2010 which has since grown to employ 70+ healthcare professionals offering a broad range of advisory services to more than 110 corporate clients in the life sciences sector. As a scientist and former equity analyst, Andrew has a strong understanding of transformative pharmaceutical products and technologies in all stages of development, and also has a strong network across healthcare institutional investors and executives. Prior to LifeSci, Andrew worked at Great Point Partners, a life sciences hedge fund, and headed healthcare research and was a publishing biotechnology analyst at ThinkEquity Partners. Prior to entering the financial services industry, Andrew was a medicinal chemist at Cytokinetics and at Pfizer.  Andrew received a Ph.D. in organic chemistry from UC Irvine and completed his B.S. in chemistry at UC Berkeley.

Andrew McDonald, PhD

Andrew co-founded LifeSci Partners in 2010 which has since grown to employ 70+ healthcare professionals offering a broad range of advisory services to more than 110 corporate clients in the life sciences sector. As a scientist and former equity analyst, Andrew has a strong understanding of transformative pharmaceutical products and technologies in all stages of development, and also has a strong network across healthcare institutional investors and executives. Prior to LifeSci, Andrew worked at Great Point Partners, a life sciences hedge fund, and headed healthcare research and was a publishing biotechnology analyst at ThinkEquity Partners. Prior to entering the financial services industry, Andrew was a medicinal chemist at Cytokinetics and at Pfizer.

Andrew received a Ph.D. in organic chemistry from UC Irvine and completed his B.S. in chemistry at UC Berkeley.

  Michael Rice   Michael Rice has experience in portfolio management, corporate management, investment banking and capital markets. Prior to co-founding LifeSci Advisors and LifeSci Capital, Michael was the co-head of health care investment banking at Canaccord Adams, where he was involved in debt and equity financing. Michael was also was a Managing Director at ThinkEquity Partners where he was responsible for managing Healthcare Capital Markets, which included structuring and executing numerous transactions, many of which were firsts at ThinkEquity. Prior to that, Michael served as a Managing Director at Banc of America serving large hedge funds and private equity healthcare funds. Previously, he was a Managing Director at JPMorgan/Hambrecht & Quist and Senior Managing Director at Bear Stearns.  Michael graduated from the University of Maryland with a degree in Economics and serves on the boards of Navidea (NAVD) and RDD Pharma.

Michael Rice

Michael Rice has experience in portfolio management, corporate management, investment banking and capital markets. Prior to co-founding LifeSci Advisors and LifeSci Capital, Michael was the co-head of health care investment banking at Canaccord Adams, where he was involved in debt and equity financing. Michael was also was a Managing Director at ThinkEquity Partners where he was responsible for managing Healthcare Capital Markets, which included structuring and executing numerous transactions, many of which were firsts at ThinkEquity. Prior to that, Michael served as a Managing Director at Banc of America serving large hedge funds and private equity healthcare funds. Previously, he was a Managing Director at JPMorgan/Hambrecht & Quist and Senior Managing Director at Bear Stearns.

Michael graduated from the University of Maryland with a degree in Economics and serves on the boards of Navidea (NAVD) and RDD Pharma.

 
  Ryan Cinalli, PhD   Ryan has over 15 years of experience in the life sciences as an investment banker, research analyst and research scientist. Prior to joining LifeSci Partners in 2018, Ryan served as a member of the healthcare investment banking team at MTS Health Partners, where he advised leading biopharma companies on strategic and equity financing engagements. Prior to MTS, he was a research analyst at LifeSci Capital where he covered oncology, immunology and inflammation. Previously, he was a research scientist at Penn, NYU and Mount Sinai, where he worked with world class academic scientists, including Craig B. Thompson, Ruth Lehmann and Philippe Soriano, to identify novel therapeutic targets for oncology and regenerative medicine. His work has been presented at major medical meetings and published in leading scientific journals, including  Cell ,  Science  and  Nature .  Ryan holds an B.S. in Biochemistry from Stockton College and completed his Ph.D. research in a Howard Hughes laboratory at the NYU School of Medicine, where he was awarded an NSF Graduate Research Fellowship for his work.

Ryan Cinalli, PhD

Ryan has over 15 years of experience in the life sciences as an investment banker, research analyst and research scientist. Prior to joining LifeSci Partners in 2018, Ryan served as a member of the healthcare investment banking team at MTS Health Partners, where he advised leading biopharma companies on strategic and equity financing engagements. Prior to MTS, he was a research analyst at LifeSci Capital where he covered oncology, immunology and inflammation. Previously, he was a research scientist at Penn, NYU and Mount Sinai, where he worked with world class academic scientists, including Craig B. Thompson, Ruth Lehmann and Philippe Soriano, to identify novel therapeutic targets for oncology and regenerative medicine. His work has been presented at major medical meetings and published in leading scientific journals, including Cell, Science and Nature.

Ryan holds an B.S. in Biochemistry from Stockton College and completed his Ph.D. research in a Howard Hughes laboratory at the NYU School of Medicine, where he was awarded an NSF Graduate Research Fellowship for his work.

  Jeremy Feffer   Jeremy brings 15 years of experience in healthcare, both as a sell-side analyst and as an investor relations advisor. Jeremy covered both medical devices and healthcare services as an analyst at Bank of America, Oppenheimer, and Cantor Fitzgerald, and he was quoted regularly in the financial press. As the founder of Whalebone Advisory, he has extensive experience developing and executing investor relations strategies for pre-IPO and publicly-traded healthcare companies and counseling senior executives on messaging to Wall Street, including guidance philosophy, earnings preparation, and corporate access plans.  Jeremy presently serves on the boards of the Edgemont Community Council and of the Fraternal Order of Bendin-Sosnowicer. Jeremy earned an MBA in Finance from the Leonard N. Stern School of Business at New York University, a Diploma in Economics from the London School of Economics, and a BA in Economics and Political Science from the University of Chicago.

Jeremy Feffer

Jeremy brings 15 years of experience in healthcare, both as a sell-side analyst and as an investor relations advisor. Jeremy covered both medical devices and healthcare services as an analyst at Bank of America, Oppenheimer, and Cantor Fitzgerald, and he was quoted regularly in the financial press. As the founder of Whalebone Advisory, he has extensive experience developing and executing investor relations strategies for pre-IPO and publicly-traded healthcare companies and counseling senior executives on messaging to Wall Street, including guidance philosophy, earnings preparation, and corporate access plans.

Jeremy presently serves on the boards of the Edgemont Community Council and of the Fraternal Order of Bendin-Sosnowicer. Jeremy earned an MBA in Finance from the Leonard N. Stern School of Business at New York University, a Diploma in Economics from the London School of Economics, and a BA in Economics and Political Science from the University of Chicago.

  Tim McCarthy, CFA   Tim brings over 18 years of investment experience across all healthcare sectors and capitalization ranges, most recently working on life science investments at Sabby Management, Kingdon Capital Management, Millennium Partners and Healthco/SAC Capital. His extensive buy-side track record, when combined with specialty pharmaceutical sell-side research at CSFB and public accounting experience at Arthur Andersen LLP, provides a well-rounded perspective to the team.  Tim earned a BS with Special Attainments in Commerce from Washington and Lee University and an MBA in Finance and International Business from the Leonard N. Stern School of Business at New York University. He is a CFA charter holder and completed all CPA qualifications.

Tim McCarthy, CFA

Tim brings over 18 years of investment experience across all healthcare sectors and capitalization ranges, most recently working on life science investments at Sabby Management, Kingdon Capital Management, Millennium Partners and Healthco/SAC Capital. His extensive buy-side track record, when combined with specialty pharmaceutical sell-side research at CSFB and public accounting experience at Arthur Andersen LLP, provides a well-rounded perspective to the team.

Tim earned a BS with Special Attainments in Commerce from Washington and Lee University and an MBA in Finance and International Business from the Leonard N. Stern School of Business at New York University. He is a CFA charter holder and completed all CPA qualifications.

  Bob Yedid   Bob has over 25 years of experience as a buy-side analyst, portfolio manager, private equity investor and investment banker. He has extensive experience with health care companies, especially in the medical technology, diagnostics and specialty pharmaceutical sectors. Bob was a Portfolio Manager and Senior Research Analyst at Principled Capital, a fund with $1.5 billion of AUM, for 10 years with responsibility for all health care investing. Prior to Principled, he was a Vice President at Warburg Pincus, one of the world’s largest private equity and venture capital firms, investing in health care. Bob was a member of the Board of Directors of The Medicines Company (MDCO) and Eurand international, which was acquired by Aptalis Pharma. He spent 15 years in investment banking, including serving as Managing Director in Health Care Finance Group at Bear Stearns & Co.  Bob earned a BA in Economics from Yale University and an MBA from Stanford University Graduate School of Business.

Bob Yedid

Bob has over 25 years of experience as a buy-side analyst, portfolio manager, private equity investor and investment banker. He has extensive experience with health care companies, especially in the medical technology, diagnostics and specialty pharmaceutical sectors. Bob was a Portfolio Manager and Senior Research Analyst at Principled Capital, a fund with $1.5 billion of AUM, for 10 years with responsibility for all health care investing. Prior to Principled, he was a Vice President at Warburg Pincus, one of the world’s largest private equity and venture capital firms, investing in health care. Bob was a member of the Board of Directors of The Medicines Company (MDCO) and Eurand international, which was acquired by Aptalis Pharma. He spent 15 years in investment banking, including serving as Managing Director in Health Care Finance Group at Bear Stearns & Co.

Bob earned a BA in Economics from Yale University and an MBA from Stanford University Graduate School of Business.